1. Inicio
  2. Publicaciones
  3. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.

Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Muñoz-Vendrell A
  • Campoy S
  • Caronna E
  • Alpuente A
  • Torres-Ferrus M
  • Campdelacreu J
  • Prat J
  • Camiña Muñiz J
  • Molina Martínez FJ
  • Mínguez-Olaondo A
  • Ruibal Salgado M
  • Santos Lasaosa S
  • Navarro Pérez MP
  • Morollón N
  • López Bravo A
  • Cano Sánchez LM
  • García-Sánchez SM
  • García-Ull J
  • Rubio-Flores L
  • Gonzalez-Martinez A
  • Quintas S
  • Echavarría Íñiguez A
  • Gil Luque S
  • Castro-Sánchez MV
  • Adell Ortega V
  • García Alhama J
  • Berrocal-Izquierdo N
  • Belvís R
  • Pozo-Rosich P
  • Huerta-Villanueva M

Abstract

BACKGROUND: Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. METHODS: In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. RESULTS: A total of 162 patients were included, median age 68 years (range 65-87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.1 ± 7.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days = 30%, = 50%, = 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). CONCLUSIONS: Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice.

© 2023. The Author(s).

Datos de la publicación

ISSN/ISSNe:
1129-2369, 1129-2377

JOURNAL OF HEADACHE AND PAIN  BMC

Tipo:
Article
Páginas:
63-63
PubMed:
37268904
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,924 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 44

Citas Recibidas en Scopus: 39

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • 65 years old; Calcitonin gene-related peptide; Migraine; Monoclonal antibodies; Real-world

Campos de Estudio

Compartir